All In Biotech

Drug Trial Radar · NCT06144749

A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

An Open Label Phase 2a Ascending Multiple Dose Safety, Efficacy, and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Adolescents and Adults With Sickle Cell Disease.

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Feb 15, 2025

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Sponsor type
Industry
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Nov 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

Conditions

  • Anemia, Sickle Cell

Interventions

  • HBI-002Drug

    Oral liquid carbon monoxide drug product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of Treatment Emergent Adverse Events, including adverse events of special interestTime frame: Day 1 to 44

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cevaxin - The Panama Clinic

    Panama City, Panama

  • Hospital Pacífica Salud

    Panama City, Panama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.